We combine deep scientific expertise and a clear strategic vision to advance precision treatments for companion animals so they can live healthier, happier and longer lives.
Cancer and chronic immune-mediated diseases remain among the most important unmet medical needs in companion animal health. While advances in human immuno-oncology have changed outcomes for many patients, advances in veterinary medicine have been slower, and treatment options often rely on repurposing human drugs that are not optimized for species-specific biology. Vetigenics was founded to address this gap.
Vetigenics is a clinical-stage animal health biotechnology company developing species-specific antibody-based immunotherapies for dogs and cats. The company’s targeted programs are uniquely generated from a complete canine discovery platform to generate treatments that deliver measurable improvements in patient outcomes while prioritizing safety, tolerability and quality of life.
THE CANIBODY PLATFORM®: Built specifically for veterinary medicine
Vetigenics’ CANIBODY Discovery Platform is a unique complete canine phage display library and a key differentiator that enables the discovery of antibodies that are naturally compatible with the canine immune system. In parallel, the company is also building a species-aware discovery strategy to support the development of therapeutics for cats.
The CANIBODY Discovery platform acts as a repeatable discovery engine, saving significant time and money in finding potential candidates. This platform supports the simultaneous discovery of multiple unique candidates and rapidly creates a robust pipeline of high-value products in species-specific immunology.
The main features are:
Rapidly identify high-affinity, target-specific antibodies tailored to species-specific immunobiology, including natural antibodies from real dogs Early candidate optimization for developability saves time and money to find potential candidates Significantly reduces the risk of immunogenicity that can compromise long-term therapy
Advances in immuno-oncology and chronic immune-mediated diseases
Vetigenics has established itself as a leader in veterinary immuno-oncology. Cancer remains one of the leading causes of death in older dogs and cats, and treatment options are limited and often focus on chemotherapy. Chemotherapy can provide benefits but is often associated with debilitating side effects and little survival benefit.
Vetigenics was one of the first companies to develop precision immunotherapies for companion animals that harness the animal’s own immune system to recognize and attack cancer cells. In human medicine, these approaches have demonstrated improved safety and survival benefits, which Vetigenics aims to replicate in veterinary patients.
Beyond oncology, Vetigenics is advancing a broad and expanding pipeline of antibodies against autoimmune diseases, allergies and osteoarthritis. These targeted, species-specific biologics have the potential to improve specificity, tolerability, and long-term disease control, creating an opportunity to redefine the standard of care in veterinary medicine.
A companion animal-first development model inspired by translation
Vetigenics was founded on principles inspired by translational medicine initiatives such as Cancer Moonshot, focused on accelerating innovation through biologically relevant patient populations. Naturally occurring diseases in dogs offer unique insights. Canine patients share environmental exposures with humans, develop spontaneous cancers and chronic diseases with similar immune involvement, and are cared for in clinically relevant settings.
Although Vetigenics does not conduct clinical research in humans, the company applies insights from human biomedical research to identify promising targets and guide the development of treatments in companion animals. The program includes preclinical safety studies in research models and clinical evaluation in pet dogs and cats. Our collaboration with veterinarians, veterinary oncologists, industry partners, and academic research institutions ensures that Vetigenics products meet the needs of today’s veterinary medicine.
Through these partnerships, Vetigenics will be able to:
Design studies that reflect real-world veterinary practice Generate high-quality translational data from patient-derived samples Incorporate clinician and owner perspectives into study design and clinical endpoints
This approach bridges discovery and clinical application, accelerating the path from antibody identification to treatments that meaningfully improve outcomes in companion animals.
Addressing external challenges in veterinary drug development
Veterinary biotechnology companies face unique structural challenges, including limited species-specific reagents, small patient populations for clinical studies, and a different regulatory environment than human drug development.
Vetigenics is proactively addressing these challenges by investing in canine-specific assays, biomarker strategies, and immune monitoring tools to help expand the ecosystem needed to support the next generation of veterinary biologics.
Owner education and trust are equally important. Transparency about study design, sample collection, and the benefits of precision antibody therapies, along with ethical responsibility, ensures Vetigenics innovation advances and strengthens trust between veterinarians and pet owners.
Building for the future of pet precision medicine
Looking to the future, Vetigenics envisions a future where precision medicine becomes an integral part of veterinary medicine and provides lasting value through species-specific biologics. The focus areas are:
Expand your antibody pipeline in areas with the greatest unmet need Integrate immune profiling and biomarker-based decision-making Identify convenient and cost-effective drug delivery approaches
Strategic collaborations with academic societies, CROs, and industry partners enable Vetigenics to scale discoveries, advance clinical programs, and effectively bring new treatments to market.
mission-driven company
Vetigenics was founded on a simple but powerful mission: to help pets live their best lives. This mission extends beyond scientific milestones to supporting veterinarians, engaging pet owners, and introducing continuous innovations to improve the lives of companion animals.
This article will be published in an upcoming Special Focus Publication on Animal Health.
Source link
